Andrea Necchi, Associate Editor at Journal of Clinical Oncology, shared on LinkedIn:
“Today marks an important day for patients with bladder cancer.
84% CR rate with TAR200 monotherapy in BCG unresponsive CIS
Sunrise1
FDA Priority Review
Here is the Journal of Clinical Oncology paper supporting these results.”
More posts featuring Bladder Cancer.